• Partnering


IO Biotech is seeking partners to expand and broaden the development of our pipeline.

Preferred collaborations 

  • Combinations trials with already approved products 
  • Combinations trials with compounds in development
  • Collaborations based on our technology platform
  • Research collaborations 

 Our capabilities 

  • Unique and novel technology platform
    • dual-mode of action vaccines targeting immune regulating proteins
    • broad pipeline of first-in-class mechanism compounds
    • robust IP estate for technology platform and vaccines
  • High throughput and agile clinical development set-up
    • two completed phase I trials
    • two ongoing phase I trials
    • three planned phase I /phase II trials
  • Solid financial position funded by experienced investors
  • Experienced management team and world class scientific and clinical advisors

Upcoming partnering events

  • BIO-Europe Spring, Amsterdam (March 2018)
  • European Lung Cancer Congress - ELCC, Geneva (April 2018)
  • DKBIO, Boston (April 2018)
  • American Association for Cancer Research - AACR, Chicago (April 2018)
  • American Society of Clinical Oncology - ASCO, Chicago (May 2018)
  • BIO International, Boston (June 2018)

For more information, please contact 

Mikkel Dybkjaer

Senior Vice President, Business Development

e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.